Blood Gas Analyzer Focuses on Safety at POC
|
By LabMedica International staff writers Posted on 29 Dec 2010 |

Image: The Roche cobas b 123 blood gas analyzer (photo courtesy Roche).
A new blood gas analyzer was designed specifically to be used at the point of care (POC).
The compact cobas b 123 is ideal for use in critical care units, emergency rooms, and other POC settings. Easy to use and virtually maintenance free, it incorporates a number of important infection control features and ensures minimal downtime with reliable, clot-free operation.
The only manual maintenance step required for the new instrument is the replacement of consumables.
Its highly durable electronics and mechanics make it robust and reliable, ensuring minimal downtime and saving time required at the machine. Clot-free operation ensures that there is no unnecessary disruption to routine or waste of reagents.
The instrument requires minimal training of staff. With touch screen operation, the system guides the user through operational processes systematically. The press of a single button is all that is required to initiate sampling and measurement.
The new analyzer has many infection control and safety features. There are no exposed needles and the protected sample input area remains closed during operation and between samples. Infection control is further enhanced by the collection of waste in a sealed pack within the closed system. Password authorization ensures safe and appropriate use by locking the instrument to unauthorized/untrained users.
The cobas b 123 includes all important critical care parameters including blood gases, hematocrit, bilirubin, electrolytes, glucose, and lactate. To make interpretation of results as easy as possible, the large, color display screen presents unambiguous readings, with measurements that fall outside predefined acceptable limits highlighted clearly.
The need for scanning barcodes and swapping the consumables across instruments is made redundant by Smart chips on the consumables (sensors, fluid packs, and quality control--QC packs). Because sensors are separate from the fluid pack, the latter can be stored at room temperature. Inventory status is displayed clearly on the screen and step-by-step prompts guide the user through the changing of consumables.
The footprint of the analyzer for environments where there is limited space is reduced by the front loading feature. Data can be transferred across instruments using a simple media card.
The new cobas b 123 POC system is the latest blood gas analyzer from Roche (Basel, Switzerland). It is due to be launched in the UK and Ireland in February 2011.
Dr. Thomas Vering, head of the Roche global sensor program, commented, "Consolidation of important critical care tests on one system allows medical professionals in critical care and emergency settings to obtain rapid answers to a broad range of medical questions. The cobas b 123 is flexible and configurable to accommodate individual needs and with its intuitive operation and excellent connectivity options, it is ideal for use at the point of care.”
Related Links:
Roche
The compact cobas b 123 is ideal for use in critical care units, emergency rooms, and other POC settings. Easy to use and virtually maintenance free, it incorporates a number of important infection control features and ensures minimal downtime with reliable, clot-free operation.
The only manual maintenance step required for the new instrument is the replacement of consumables.
Its highly durable electronics and mechanics make it robust and reliable, ensuring minimal downtime and saving time required at the machine. Clot-free operation ensures that there is no unnecessary disruption to routine or waste of reagents.
The instrument requires minimal training of staff. With touch screen operation, the system guides the user through operational processes systematically. The press of a single button is all that is required to initiate sampling and measurement.
The new analyzer has many infection control and safety features. There are no exposed needles and the protected sample input area remains closed during operation and between samples. Infection control is further enhanced by the collection of waste in a sealed pack within the closed system. Password authorization ensures safe and appropriate use by locking the instrument to unauthorized/untrained users.
The cobas b 123 includes all important critical care parameters including blood gases, hematocrit, bilirubin, electrolytes, glucose, and lactate. To make interpretation of results as easy as possible, the large, color display screen presents unambiguous readings, with measurements that fall outside predefined acceptable limits highlighted clearly.
The need for scanning barcodes and swapping the consumables across instruments is made redundant by Smart chips on the consumables (sensors, fluid packs, and quality control--QC packs). Because sensors are separate from the fluid pack, the latter can be stored at room temperature. Inventory status is displayed clearly on the screen and step-by-step prompts guide the user through the changing of consumables.
The footprint of the analyzer for environments where there is limited space is reduced by the front loading feature. Data can be transferred across instruments using a simple media card.
The new cobas b 123 POC system is the latest blood gas analyzer from Roche (Basel, Switzerland). It is due to be launched in the UK and Ireland in February 2011.
Dr. Thomas Vering, head of the Roche global sensor program, commented, "Consolidation of important critical care tests on one system allows medical professionals in critical care and emergency settings to obtain rapid answers to a broad range of medical questions. The cobas b 123 is flexible and configurable to accommodate individual needs and with its intuitive operation and excellent connectivity options, it is ideal for use at the point of care.”
Related Links:
Roche
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







